YOLFTbeta
Context Therapeutics Inc

Context Therapeutics Inc

CNTX · NASDAQ · Healthcare / Biotechnology

0.1808USD-0.02 (-8.69%)

Price History

Full chart

Market Stats

Previous Close0.198
Open0.20
Day Range0.1801 – 0.2065
52-Week Range0.343 – 3.62
Volume931.68K
Market Cap31.76M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.48
Dividend Yield0.00%
Beta1.69
50-Day Avg0.4793
200-Day Avg1.59

About

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Martin A. Lehr
  • Employees15
  • Headquarters2001 Market Street, Philadelphia, PA, United States, 19103, USA
  • Websitehttps://www.contexttherapeutics.com

Leadership

  • Mr. Martin A. LehrCo-Founder, President, CEO & Director · b. 1984
  • Ms. Jennifer Minai-AzaryCFO & Treasurer · b. 1978
  • Mr. Alex C. Levit Esq., J.D.Chief Legal Officer & Corporate Secretary · b. 1979
  • Mr. Christopher Beck M.B.A.Senior Vice President of Operations
  • Mr. Jeffrey LiebmanAssociate Director of Accounting
  • Ms. Jennifer Dashnau M.B.A., Ph.D.Senior Vice President of Technical Operations
  • Dr. Karen Chagin M.D.Chief Medical Officer · b. 1977

Financials

Income Statement

Currency: USD2016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000000000
Cost of Revenue00---9.27K12.04K52.70K124.66K
Gross Profit00----9.27K-12.04K-52.70K-124.66K
Operating Expense33.23M24.05M---15.37M25.06M29.87M39.58M
Operating Income-33.23M-24.05M-5.38M-2.57M-10.53M-15.38M-25.07M-29.92M-39.70M
EBITDA---5.38M-2.57M-10.53M-14.87M-23.95M-26.71M-36.11M
Net Income-37.67M-24.61M-7.48M6.64M-10.46M-14.84M-23.96M-26.73M-36.12M
R&D27.79M17.62M2.41M1.64M3.81M7.09M17.78M22.70M31.86M
Interest Expense001.10M661.22K64.24K547.27K---

Balance Sheet

Currency: USD2016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets24.01M68.34M273.55K467.34K51.31M37.97M16.06M98.13M68.49M
Total Liabilities10.89M9.38M24.23M17.39M3.03M3.21M4.19M2.86M8.02M
Total Equity13.12M58.95M-23.96M-16.92M48.27M34.76M11.87M95.27M60.47M
Cash16.23M60.68M226.60K341.04K49.64M35.50M14.45M94.43M66.00M
Total Debt--21.84M5.95M-55.08K-219.38K112.06K
Net Debt--21.62M5.61M-49.64M-35.44M-14.45M-94.21M-65.88M

Cash Flow

Currency: USD2016-12-312017-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-30.57M-22.35M-2.84M-1.03M-8.80M-13.55M-21.05M-14.56M-26.39M
Investing Cash Flow-28.00K-28.00K-250.00K-250.00K-250.00K-536.84K--14.76M-2.03M
Financing Cash Flow44.18M66.83M1.96M1.15M58.39M-102.07K0109.29M-15.27K
Capital Expenditure28.00K28.00K00250.00K536.84K014.76M33.95K
Free Cash Flow---2.84M-1.03M-9.05M-14.09M-21.05M-29.31M-26.42M
FCF to OCF--100.00%100.00%102.84%103.96%100.00%201.39%100.13%

Earnings

Report DateNov 9, 2018Jul 2, 2021Oct 19, 2021Mar 23, 2022May 11, 2022Aug 11, 2022Nov 9, 2022Mar 22, 2023May 10, 2023Aug 9, 2023Nov 9, 2023Mar 21, 2024May 8, 2024Aug 7, 2024Nov 6, 2024Mar 20, 2025May 7, 2025Aug 6, 2025Nov 5, 2025Mar 25, 2026May 6, 2026Aug 5, 2026Nov 4, 2026
EPS Estimate0.000.000.00-0.58-0.24-0.25-0.25-0.22-0.19-0.20-0.31-0.35-0.44-0.07-0.09-0.06-0.06-0.05-0.09-0.10-0.12-0.10-0.09
EPS Actual-0.880.97-0.46-0.58-0.22-0.25-0.24-0.22-0.40-0.31-0.37-0.42-0.23-0.04-0.22-0.03-0.05-0.09-0.10-0.14-0.09-0.15-
Surprise---0.00%8.33%0.00%4.00%0.00%-110.53%-55.00%-19.35%-20.00%47.73%42.86%-144.44%47.09%16.67%-80.00%-11.11%-36.59%25.00%-50.00%-
Timing----After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hours-After-hoursAfter-hours-

Key Statistics & Ratios

Market Cap31.76M
Enterprise Value-7.15M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book0.93
EPS-0.48
Book Value0.415
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-48.71M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-76.14%
Return on Assets-45.70%
Shares Outstanding91.88M
Shares Float63.73M
Beta1.69
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 4.25
  • Strong Buy
    2
  • Buy
    3

Ownership Breakdown

Institutions
69.14%
Insiders
1.57%
Retail / Other
29.29%

Top Institutional Holders

  • Deep Track Capital, LP
    7.42M8.08%
  • Nextech Invest, Ltd.
    7.42M8.08%
  • Soleus Capital Management, L.P.
    7.06M7.69%
  • Avidity Partners Management LP
    5.00M5.44%
  • Franklin Templeton Inc
    3.80M4.14%
  • Vanguard Capital Management, LLC
    3.43M3.74%
  • Octagon Capital Advisors LP
    3.05M3.32%
  • Marshall Wace Asset Management Ltd
    2.95M3.21%
  • Blue Owl Capital Holdings LP
    2.93M3.19%
  • TCG Crossover Management, LLC
    2.68M2.92%
  • MPM Oncology Impact Management LP
    1.30M1.41%
  • Susquehanna International Group, LLP
    1.09M1.19%
  • BlackRock Inc
    846.70K0.92%
  • Geode Capital Management, LLC
    603.77K0.66%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.82M3.06%
  • Franklin Biotechnology Discv A(acc)USD
    2.40M2.62%
  • iShares Russell 2000 ETF
    2.29M2.50%
  • Fidelity Small Cap Index
    1.01M1.10%
  • iShares Russell 2000 Growth ETF
    881.59K0.96%
  • Vanguard Russell 2000 ETF
    540.48K0.59%